33.83

0.88% -0.30

Pre-market: 33.43 -0.40 -1.18%

Rapport Therapeutics Inc (RAPP)

Overview News Price History Discussions Forecast

Rapport Therapeutics Inc stock is traded at $33.83, with a volume of 848.48K. It is down -0.88% in the last 24 hours and down -31.42% over the past month. Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Previous Close:

$34.13

Open:

$34.15

24h Volume:

848.48K

Relative Volume:

2.18

Market Cap:

$1.62B

Revenue:

Net Income/Loss:

$-107.28M

P/E Ratio:

-13.00

EPS:

-2.6031

Net Cash Flow:

$-80.71M

1W Performance:

-19.36%

1M Performance:

-31.42%

6M Performance:

+19.75%

1Y Performance:

+25.48%

1-Day Range:

$31.58

$34.21

1-Week Range:

$31.58

$43.00

52-Week Range:

$23.75

$52.93

Rapport Therapeutics Inc Stock (RAPP) Company Profile

Name

Rapport Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

857-321-8020

Address

99 HIGH STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

RAPP's Discussions on Twitter

Compare RAPP vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPP Rapport Therapeutics Inc	33.83	1.62B	0	-107.28M	-80.71M	-2.6031
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Strong Buy
Feb-02-26	Initiated	Wells Fargo	Overweight
Nov-19-25	Initiated	BTIG Research	Buy
Sep-16-25	Initiated	Truist	Buy
Aug-06-25	Initiated	H.C. Wainwright	Buy
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	Jefferies	Buy
Jul-02-24	Initiated	Stifel	Buy
Jul-02-24	Initiated	TD Cowen	Buy

View All

Rapport Therapeutics Inc Stock (RAPP) Latest News

Sep 24, 2026

Form 4 Rapport Therapeutics Inc For: 24 September - Investing.com India

Sep 24, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com

Sep 24, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com Canada

Sep 24, 2026

Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com UK

Sep 24, 2026

Rapport Therapeutics shares drop 18% on updates for RAP-219 and upcoming bipolar mania trial data - Pluang

Sep 24, 2026

Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med (NASDAQ:RAPP) - Seeking Alpha

Sep 24, 2026

Analysts Conflicted on These NA Names: General Dynamics (GD), Rapport Therapeutics, Inc. (RAPP) and First Solar (FSLR) - The Globe and Mail

Sep 24, 2026

Sep 23, 2026